Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

ZevaquenabantAlso known as MRI-1867

Hybrid inhibitor of peripheral CB1 and iNOS, studied in mice in models of fibrosis and dyslipidaemia.

Level of detail

C₂₅H₂₁ClF₃N₅O₂S

CAS 1998760-00-1

Family
ECS pharmacological toolAntagonist or inverse agonist
Molar mass
548.00 g/mol

Updated on

In plain terms

Zevaquenabant (MRI-1867) blocks both the CB1 receptor and an enzyme that produces nitric oxide, iNOS; it is designed to act outside the brain. In mice, it attenuated models of skin and lung fibrosis and of dyslipidaemia. It remains an experimental compound, with no marketing authorisation.

Receptors and activity

Target network

CB1Inverse agonisthigh-affinity antagonist/inverse agonist, peripherally restricted (Kumari et al. 2024); the (R) enantiomer inactive at CB1; no Ki value in the texts consulted
  • Blocks or inhibits

The lower the cited value, the closer the target sits to Zevaquenabant: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of Zevaquenabant.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Cited values

  1. CB1Inverse agonistno measured value cited

    high-affinity antagonist/inverse agonist, peripherally restricted (Kumari et al. 2024); the (R) enantiomer inactive at CB1; no Ki value in the texts consulted

  2. iNOSInhibitorno measured value cited

    hybrid iNOS inhibitor; the (R) enantiomer retains this activity (Roger et al. 2020); no numerical value in the texts consulted

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Measured effects

Not characterised. No placebo-controlled human trial has measured the effects of Zevaquenabant, so no level is shown.

Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method

Pharmacology

Zevaquenabant, known in the literature as MRI-1867 or S-MRI-1867, is a hybrid inhibitor: a peripherally restricted antagonist and inverse agonist of CB1 and an inhibitor of iNOS (Kumari et al. 2024; Zawatsky et al. 2021). It was designed at the NIAAA/NIH by the team of Kunos, Iyer and Cinar. In mice, simultaneous inhibition of both targets gave a greater antifibrotic efficacy than inhibition of either target alone in models of liver, lung and kidney fibrosis (Zawatsky et al. 2021). In bleomycin-induced skin fibrosis, the compound attenuated established fibrosis in mice lacking the MDR1 and BCRP transporters, but not in C57BL/6 mice: the skin concentration of MRI-1867, an MDR1 substrate, was 0.023 µM in the latter against 8.8 µM in the former, bleomycin increasing MDR1 efflux activity in fibrotic skin (Zawatsky et al. 2021). In bleomycin-induced pulmonary fibrosis, pulmonary delivery of 0.5 mg/kg/day was as effective as systemic delivery of 10 mg/kg/day and matched nintedanib; the compound also attenuated fibrosis and pro-fibrotic mediators in human lung slices (Basu et al. 2025). In obese mice, the (S) enantiomer reduced hepatic steatosis and hepatic VLDL secretion (Roger et al. 2020). The data are preclinical; no clinical data were found in the sources consulted.

History

Source
Entirely synthetic compound with no known natural occurrence. It comes from NIH pharmaceutical research and is not marketed (no marketing authorisation found).

Origin

Research tool

No known biosynthetic pathway: a synthetic molecule. It is a dihydropyrazole carboximidamide of (S) configuration, (NE,4S)-N-(1-aminoethylidene)-5-(4-chlorophenyl)-4-phenyl-N'-[4-(trifluoromethyl)phenyl]sulfonyl-3,4-dihydropyrazole-2-carboximidamide (name read on PubChem, CID 155321421).

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Antagonist or inverse agonist

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

Zevaquenabant (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

Common name
Zevaquenabant (MRI-1867)
IUPAC name
(NE,4S)-N-(1-aminoethylidene)-5-(4-chlorophenyl)-4-phenyl-N'-[4-(trifluoromethyl)phenyl]sulfonyl-3,4-dihydropyrazole-2-carboximidamide
Other names
MRI-1867 · S-MRI-1867 · INV-101 · Zevaquenabant

Identifiers

Formula
C₂₅H₂₁ClF₃N₅O₂S
CAS
1998760-00-1
InChIKey
NLXIJZHFEOSWPU-JOCHJYFZSA-N
SMILES
CC(=N)N=C(NS(=O)(=O)c1ccc(C(F)(F)F)cc1)N1C[C@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.